You just read:

Amgen Receives CHMP Positive Opinion To Expand Use Of BLINCYTO® (Blinatumomab) In Patients With Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia

News provided by

Amgen

Nov 16, 2018, 09:00 ET